In today’s competitive oncology landscape, researchers are under pressure to ensure their clinical trial designs are both innovative and efficient. It’s increasingly common for trials to incorporate multiple therapies and diseases. At the same time, oncology researchers often try to answer numerous complex hypotheses in one study.
Join this October 1 webinar to gain insights to drive faster and more efficient development in oncology. You’ll hear about complex innovative trial design approaches in oncology clinical development and maximizing the speed of molecule development. The next segment will explore challenges in designing a complex innovative clinical trial program from a statistical and regulatory perspective. Finally, you will learn about the application and value of biomarkers in adaptive oncology trial designs today and perspectives on the future.
This webinar is part of a scientific series Covance is offering focused on trends, opportunities and challenges associated with current and future applications in Oncology. Learn more and register for upcoming webinars on topics such as adoptive T-cell therapies, biomarker technologies for the detection of rare cancer driver mutations and novel targeted therapies, and more.
Dr. Sarah Blagden, Associate Professor of Medical Oncology, University of Oxford
Dr. Sarah Blagden is an Associate Professor of Medical Oncology at the University of Oxford. She undertook her specialist training in Cambridge and the Royal Marsden Hospital London. From 2006-2015, she was Senior Lecturer at Imperial College before moving to University of Oxford in 2015. There, Dr. Blagden directs the Early Phase Cancer Trials Unit, is their ECMC lead and runs a basic science laboratory.Message Presenter
Maria J. Prendes, PhD, MS, Head of Oncology, Biomarker Solution Center, Covance
Dr. Maria Prendes leads the oncology therapeutic team for Covance Biomarker Solution Center (BSC). She brings over 15 years of drug development experience to her work with clients and internal labs to drive biomarker studies. She provides clients with insights on biomarker selection, characterization and development for their clinical trials. Dr. Prendes also supports Companion Diagnostics (CDx) through her work with existing SMEs and business development staff.Message Presenter
Who Should Attend?
- Chief Development Officers
- Operational Directors
- Clinical Development Directors
- Clinical Operations Personnel
- Clinical Scientists
What You Will Learn
Attendees will learn about:
- Complex Innovative Design (CID) for clinical trial program development including master protocols (basket and umbrella), phase-less trial designs and other approaches with clinical utilization
- Suitability of biomarker selection in driving faster operational delivery in complex innovative design in clinical trials
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.
Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.
Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.